1.
Kuruvilla FG, Shamji AF, Sternson SM, Hergenrother PJ, Schreiber SL. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature. 2002;416(6881):653-7. doi:10.1038/416653a.
1.
Hardwick JS, Kuruvilla FG, Tong JK, Shamji AF, Schreiber SL. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc Natl Acad Sci U S A. 1999;96(26):14866-70.
1.
Tramer F, Vetere A, Martinelli M, et al. cAMP-response element modulator-tau activates a distinct promoter element for the expression of the phospholipid hydroperoxide/sperm nucleus glutathione peroxidase gene. Biochem J. 2004;383(Pt 1):179-85. doi:10.1042/BJ20040974.
1.
Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453-457. doi:10.1038/nature23007.
1.
Zou Y, Palte MJ, Deik AA, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10(1):1617. doi:10.1038/s41467-019-09277-9.
1.
Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247-250. doi:10.1038/nature24297.
1.
Liu H, Schreiber SL, Stockwell BR. Targeting Dependency on the GPX4 Lipid Peroxide Repair Pathway for Cancer Therapy. Biochemistry. 2018;57(14):2059-2060. doi:10.1021/acs.biochem.8b00307.
1.
Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1-2):317-31. doi:10.1016/j.cell.2013.12.010.
1.
Shema R, Kulicke R, Cowley GS, Stein R, Root DE, Heiman M. Synthetic lethal screening in the mammalian central nervous system identifies Gpx6 as a modulator of Huntington’s disease. Proc Natl Acad Sci U S A. 2015;112(1):268-72. doi:10.1073/pnas.1417231112.